* Co has lost $65 mln in market cap since Feb rejection of Vitaros (Adds details on options, background, shares) April 16 (Reuters) - Apricus Biosciences Inc said on Monday it was considering options ...
(Reuters) - The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the ...
Apricus Biosciences, Inc.’s APRI shares gained 7.7% after the company announced that it has entered into a license agreement with Allergan AGN under which it will regain the U.S. development and ...
Apricus Biosciences, Inc.APRI announced that its topical cream, Vitaros for the treatment of erectile dysfunction (ED) has been launched in Lebanon by partner Elis Pharmaceuticals Ltd. Apricus' share ...
SAN DIEGO, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), announced today that Apricus signed an exclusive license ...
A woman ended up in A&E after she was prescribed erectile dysfunction cream to treat a dry eye by mistake. The anonymous patient, from Glasgow, was given Vitaros cream instead of the eye lubricant ...
(Reuters) - Apricus Biosciences Inc said on Monday it was considering options for the company and looking to sell the U.S. rights to its erectile dysfunction cream Vitaros, after the Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results